Carrie Cox

Carrie Cox serves as Chairman of the Board of Directors. Ms. Cox has served as an Executive Chairman of Humacyte, Inc., a privately-held regenerative medical technology company, since January 2018. She joined Humacyte in 2010 and served as its Chief Executive Officer and Director between 2010 and 2018 and as its Chief Executive Officer and Chairman of the Board between 2013 and 2018. Ms. Cox served as Executive Vice President of Schering-Plough and President of Schering-Plough’s Global Pharmaceutical Business from 2003 until November 3, 2009, when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s Pharmaceutical Business from 1997 until its merger with Pfizer Inc. in 2003. She also currently serves on the Board of Directors of Texas Instruments Inc., Cardinal Health Inc. and Selecta Biosciences, Inc. She has previously served on the Board of Directors of Celgene Corp. from 2009 until its acquisition by Bristol-Myers Squibb Co. in 2019 and on the Board of Directors of Array BioPharma, Inc. from 2018 until its acquisition by Pfizer Inc. in 2019. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.